Akari Therapeutics, Plc Investing Cash Flow
Akari Therapeutics, Plc (AKTX) reported Investing Cash Flow of $382.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-30
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for the quarter ending 2016-03-31 was -$42.08K.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for the quarter ending 2015-12-31 was -$18.78K.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for the quarter ending 2015-09-30 was $1.41M, a 893.36% increase year-over-year.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for the quarter ending 2015-06-30 was $0.00.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for fiscal 2024 was $382.00K.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for fiscal 2014 was $0.00.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for fiscal 2013 was $0.00.
- Akari Therapeutics, Plc net cash provided by (used in) investing activities for fiscal 2012 was $0.00.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed | Net Cash Provided by (Used in) Investing Activities 99 month | Net Cash Provided by (Used in) Investing Activities 111 month |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | $382.00K 10-K · filed 2026-03-30 | ||||||
| 2024-06-30 | $66.50K 8-K · filed 2024-09-06 | ||||||
| 2023-12-31 | $0.00 8-K · filed 2024-09-06 | ||||||
| 2023-06-30 | $0.00 8-K · filed 2024-09-06 | ||||||
| 2022-12-31 | -$142.25K 8-K · filed 2024-09-06 | ||||||
| 2019-12-31 | $0.00 20-F · filed 2020-03-31 | ||||||
| 2018-12-31 | $0.00 20-F · filed 2020-03-31 | ||||||
| 2018-06-30 | -$379.07K 6-K · filed 2018-09-27 | ||||||
| 2017-12-31 | $9.99M 20-F · filed 2020-03-31 | ||||||
| 2017-06-30 | $9.99M 6-K · filed 2018-09-27 | ||||||
| 2016-12-31 | -$10.07M 20-F · filed 2019-04-23 | ||||||
| 2016-03-31 | -$42.08K 10-Q · filed 2016-05-12 | -$60.86K derived: sum of 2 quarters · filed 2018-07-18 | $1.35M derived: sum of 3 quarters · filed 2018-07-18 | $1.35M derived: sum of 4 quarters · filed 2018-07-18 | |||
| 2015-12-31 | -$18.78K derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | $1.39M derived: sum of 2 quarters · filed 2018-07-18 | $1.39M derived: sum of 3 quarters · filed 2018-07-18 | $1.39M 20-F · filed 2018-07-18 | |||
| 2015-09-30 | $1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-23 | $1.41M derived: sum of 2 quarters · filed 2015-11-23 | $1.41M 10-Q · filed 2015-11-23 | $1.41M derived: sum of 4 quarters · filed 2016-05-12 | |||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $0.00 10-Q · filed 2015-08-12 | $0.00 derived: sum of 3 quarters · filed 2016-05-12 | $142.00K derived: sum of 4 quarters · filed 2016-05-12 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-12 | $0.00 derived: sum of 2 quarters · filed 2016-05-12 | $142.00K derived: sum of 3 quarters · filed 2016-05-12 | $0.00 derived: sum of 4 quarters · filed 2016-05-12 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $142.00K derived: sum of 2 quarters · filed 2016-03-23 | $0.00 derived: sum of 3 quarters · filed 2016-03-23 | $0.00 10-K · filed 2016-03-23 | -$199.00K 10-K · filed 2015-02-11 | ||
| 2014-09-30 | $142.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-23 | $0.00 derived: sum of 2 quarters · filed 2015-11-23 | $0.00 10-Q · filed 2015-11-23 | ||||
| 2014-06-30 | -$142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$142.00K 10-Q · filed 2015-08-12 | |||||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-12 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2015-02-11 | -$10.00K 20-F · filed 2014-03-24 | |||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-11 | -$9.00K 20-F/A · filed 2013-04-19 | |||||
| 2011-12-31 | $0.00 20-F · filed 2014-03-24 | ||||||
| 2010-12-31 | $0.00 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |